Overview

Safety, Tolerability and Pharmacokinetics of SP-8203

Status:
Completed
Trial end date:
2015-03-11
Target enrollment:
Participant gender:
Summary
Phase I study in health volunteers to assess the safety, tolerability and pharmacokinetics of escalating single doses and multiple doses of SP-8203
Phase:
Phase 1
Details
Lead Sponsor:
Shin Poong Pharmaceutical Co. Ltd.
Treatments:
Otaplimastat